Alexis Koskan1, Morgan E Zittel2, Chong Lee3, Omar Sanchez4, Linda Alvarez5, Deborah L Helitzer6. 1. Arizona State University College of Health Solutions, mail: 425 N 5th Street, Phoenix, AZ, 85004, USA. Electronic address: alexis.koskan@asu.edu. 2. Arizona State University, USA. Electronic address: mzittel@asu.edu. 3. Arizona State University College of Health Solutions, USA. Electronic address: chong.lee@asu.edu. 4. Arizona State University, USA. Electronic address: osanche31@gmail.com. 5. Arizona State University, USA. Electronic address: Lindaa3430@yahoo.com. 6. Arizona State University College of Health Solutions, USA. Electronic address: deborah.helitzer@asu.edu.
Abstract
OBJECTIVE: Immunizing pharmacists can administer vaccines; however, they are less likely to administer adolescent vaccines such as vaccines that protect against human papillomavirus (HPV). Although past research has recommended incorporating pharmacists to increase adolescent vaccination, few intervention studies have tested healthcare delivery models that incorporate pharmacists to aid in vaccine series completion. This research explored the feasibility and acceptability of an intervention in which pharmacists administered booster doses of the HPV vaccine series. METHODS: Between April 2019 and February 2020, the research team recruited participants for a pilot randomized controlled trial hosted in one federally qualified health center (FQHC) clinic. Researchers asked intervention group participants to complete the HPV vaccine series with their community pharmacists and control group participants to complete the series at their FQHC. We conducted a pre- and post-intervention surveys and in-depth interviews with both intervention and control group participants. RESULTS: A total of 33 parents of children who received the first dose of the HPV vaccine enrolled in the study of whom 8 intervention and 11 control group participants completed post-intervention data collection. Although there were no statistically significant changes in vaccine completion and in psychometric variables, we did find that pharmacist-delivered HPV vaccination was acceptable, due, primarily, to convenience. Barriers to receiving pharmacist-administered vaccines included pharmacies' lack of stocking the vaccine and insurance-related barriers to care. CONCLUSION: Although a promising and acceptable healthcare delivery approach, there are still barriers for caregivers to have their children vaccinated against HPV at their community pharmacies.
OBJECTIVE: Immunizing pharmacists can administer vaccines; however, they are less likely to administer adolescent vaccines such as vaccines that protect against human papillomavirus (HPV). Although past research has recommended incorporating pharmacists to increase adolescent vaccination, few intervention studies have tested healthcare delivery models that incorporate pharmacists to aid in vaccine series completion. This research explored the feasibility and acceptability of an intervention in which pharmacists administered booster doses of the HPV vaccine series. METHODS: Between April 2019 and February 2020, the research team recruited participants for a pilot randomized controlled trial hosted in one federally qualified health center (FQHC) clinic. Researchers asked intervention group participants to complete the HPV vaccine series with their community pharmacists and control group participants to complete the series at their FQHC. We conducted a pre- and post-intervention surveys and in-depth interviews with both intervention and control group participants. RESULTS: A total of 33 parents of children who received the first dose of the HPV vaccine enrolled in the study of whom 8 intervention and 11 control group participants completed post-intervention data collection. Although there were no statistically significant changes in vaccine completion and in psychometric variables, we did find that pharmacist-delivered HPV vaccination was acceptable, due, primarily, to convenience. Barriers to receiving pharmacist-administered vaccines included pharmacies' lack of stocking the vaccine and insurance-related barriers to care. CONCLUSION: Although a promising and acceptable healthcare delivery approach, there are still barriers for caregivers to have their children vaccinated against HPV at their community pharmacies.
Authors: Joseph P Fava; Jacob Colleran; Francesca Bignasci; Raymond Cha; Paul E Kilgore Journal: Hum Vaccin Immunother Date: 2017-06-12 Impact factor: 3.452
Authors: Parth D Shah; Macary W Marciniak; Shelley D Golden; Justin G Trogdon; Carol E Golin; Noel T Brewer Journal: Vaccine Date: 2018-05-07 Impact factor: 3.641
Authors: Tanja Y Walker; Laurie D Elam-Evans; James A Singleton; David Yankey; Lauri E Markowitz; Benjamin Fredua; Charnetta L Williams; Sarah A Meyer; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2017-08-25 Impact factor: 17.586
Authors: Virginia Senkomago; S Jane Henley; Cheryll C Thomas; Jacqueline M Mix; Lauri E Markowitz; Mona Saraiya Journal: MMWR Morb Mortal Wkly Rep Date: 2019-08-23 Impact factor: 17.586
Authors: Patricia A Carney; Sarah Bumatay; Grace M Kuo; Paul M Darden; Andrew Hamilton; Lyle J Fagnan; Brigit Hatch Journal: Prev Med Rep Date: 2022-07-04